Hepatitis C virus-related lymphoproliferative disorders: An overview

Table 3 Combined IFN (recombinant or pegylated) + ribavirin therapy in HCV-related mixed cryoglobulinemia

Author	Year	No. patients	Treatment	CS	Treatment duration (months)	EOT response	Sustained response
Durand	1998	5 NR	RBV	No	10-36	100%	0%
Calleja	1999	18	3 MIU IFN × 3/w	No	12	55%	28%
		8 NR	3 MIU IFN × 3/w + RBV	No	12	63%	38%
Zuckerman	2000	9 NR	3 MIU IFN × 3/w + RBV	No	6	78%
Cacoub	2002	14	Variable IFN + RBV	variable	6-56		71%
Mazzaro	2003	27 NR or Rel	3 MIU × 3/w + RBV	No	12	85%
Alric	2004	18	3 MIU × 3/w or Peg-IFN + RBV	No	≥ 18		70%
Cacoub	2005	9	Peg-IFN 1.5 μg Kg-1 w-1 + RBV		≥ 10		88%
Mazzaro	2005	18	Peg-IFN 1 μg Kg-1 w-1 + RBV	No	12	89%	44%

CS: corticosteroids; MIU: millions of international units; d: day; m: months; w: week; EOT: end of treatment; NR: non responders; Rel: relapser; RBV: ribavirin. From: Zignego A.L. Postgraduate Course of the 41st Annual Meeting of the EASL, 2006.